TABLE 1.
Mangiferin against cancers.
| Type of cancer | Study | Intervention | Result | Reference |
|---|---|---|---|---|
| Breast cancer | In vivo: xenograft mouse model using MCF‐7 cells (mammary carcinoma) | Mangiferin at 100 mg/kg (oral) for 72 h | Inhibition of the development of MCF‐7 breast cancer cells, with respect to time | Zhang et al. (2020) |
| Breast cancer | Within living organisms: Cytotoxic mangiferin's impact on MDA‐MB‐231 (xenograft mice) | Mangiferin at 100 milligrams per kilogram for 4 days | Dose‐responsive suppression of MDA‐MB‐231 and MCF‐7 growth tumor substance | Deng et al. (2018) |
| Colon cancer | In vivo: Albino rat colon carcinogenesis | 0.1% mangiferin for 48 h | 65%–85% decrease in colonic mucosal cell proliferation | Samadarsi et al. (2022) |
| Colon cancer | In vitro: Characterization of cytotoxic effect of mangiferin on HeLa cells | 48 h of exposure to 10 μg/mL mangiferin | Significant reduction in tumor nodule formation | Lauricella et al. (2019) |
| Liver cancer | In vivo: Healthy Sprague–Dawley rats hepatocellular carcinoma | Mangiferin at 50 mg for 12 weeks | Significant reduction in tumor nodule formation | Yang et al. (2019) |
| Liver cancer | In vivo: Mangiferin's inhibitory impact on liver of mice | Mangiferin taking 5 milligrams per kilogram of body weight, taken orally for a period of six days | Reduced proliferation on liver cell within a dose‐ and in a time‐dependent way | Tao et al. (2023) |
| Gastric cancer | In vitro: Antiproliferative mangiferin's impact on SGC‐7901 cells | Applying mangiferin for 24, 48, and 72 h at 16.00, 8.63, and 4.79 μmol/L | Caused gastric cancer cells to undergo apoptosis by blocking PI3K/Akt pathways | Du et al. (2018) |
| Gastric cancer | In vivo: Gastroprotective effect of mangiferin on 4‐h rats ligated with pylorus | Mangiferin at 3, 10, and 30 milligrams per kilogram of body weight for 48 h | 50% and 76% of gastric damage suppression | Chi et al. (2021) |
| Ovarian cancer | In vivo: Cytotoxic effects of mangiferin on OVCAR8 cell (xenograft mice model) | Mangiferin at (8, 16, or 20 μM) for 20 days | Mangiferin boosted the cytotoxic effects on ovarian cancer cells | Kuroki and Guntupalli (2020) |
| Ovarian cancer | In vivo: Nude ES‐2 mouse xenograft model | 24 h of exposure of mangiferin at 5, 10, and 25 μM | Inhibited the development of ovarian epithelial carcinoma in a dose‐dependent way | Zeng et al. (2020) |
| Prostate cancer | In vitro: Effect of mangiferin on PC3 cells | Mangiferin at (0, 10, 20, and 40 μM) for 72 h | Significantly reduced Bcl‐2 expression levels and boosted apoptotic death | Sarfraz et al. (2023) |
| Prostate cancer | In vitro: Mangiferin's cytotoxic effect on LNCaP cancer cells | 24 h of exposure to mangiferin at (15 mol/mL) | Significantly reduced raises miR‐182 expression and Bcl‐2 expression levels | Khoobchandani et al. (2021) |
| Blood cancer | In vitro: Human leukemia cells HL‐60 | (50 μmol/L) of mangiferin for 24 h | Reduced the expansion of HL‐60 cells within a dose‐reliant way | Ayatollahi et al. (2019) |
| Blood cancer | In vivo: BALB/c mice | 40, 80, and 20 days of 120 mg/kg of Mangiferin | The survival rate was dramatically increased by mangiferin at 40 and 120 mg/kg | Morozkina et al. (2021) |
| Lung cancer | In vivo: Healthy Swiss albino mouse‐male | Mangiferin (100 mg/kg at body weight) after 20 days | Inhibition of growth of lung cancer cells in a dose‐dependent way | Spampinato et al. (2022) |
| Lung cancer | In vivo: Swiss albino mice | Mangiferin administered orally (100 mg kg−1 b/w) for 18 weeks | Inhibition in the growth of lung cancer cells with chemoprotective effect in a dose‐dependent way | Razura‐Carmona et al. (2022) |
| Kidney cancer | In vivo: Male wistar albino rats | For 10 days, mangiferin at 10, 20, and 40 mg/kg | Significant reduction in tumor nodule formation | Du et al. (2020) |
| Kidney cancer | In vitro: Effect of dose dependency of mangiferin using Nike cells | 25 μM of mangiferin for 24 h | Ameliorative effect of mangiferin by upregulating through PI3K activation, Nrf‐2 displays synergistic anticancer action | Lum et al. (2022) |
| Bone cancer | In vitro: Effect of mangiferin on Saos‐2 and U2OS cells | 25, 50, 75, and 100 μM of mangiferin for 24 h | Reduced proliferation of osteosarcoma | Wen et al. (2020) |
| Bone cancer | In vivo: Inhibitory effect of mangiferin on rats | Mangiferin at 10 mg/kg/day | Antiresorptive effect of mangiferin reduced the bone alterations | Rahmani et al. (2023) |
| Brain cancer | In vivo: Mangiferin's impact on DOX‐induced Sprague–Dawley male rats | Mangiferin after 7 months at a time between 30 and 60 mg/kg bw | Reduced oxidative stress and inflammation had neuroprotective impact on brain damage | Morozkina et al. (2021) |